Search - tctmd.com

Displaying 261 - 280 of 485

Sort: Relevancy | Date

Presentation TCT 2016

The Great Absorb Debate: Is Absorb Ready To Be Used In Most Patients And Lesions? Yes With Proper Technique And Planning, Nearly All PCI Patients Can Benefit From BVS!

Presenter: Stephen G. Ellis, Corrado Tamburino, Massimo Napodano

October 31, 2016

Presentation TCT 2016

Outcome Registries VII: IT-DISAPPEARS

Presenter: Stephen G. Ellis, Corrado Tamburino, Anna Sonia Petronio

October 31, 2016

Presentation TCT 2016

Outcome Registries VI: France ABSORB

Presenter: Stephen G. Ellis, Corrado Tamburino, Didier Carrié

October 31, 2016

Presentation TCT 2016

Outcome Registries V: New Insights From GHOST

Presenter: Stephen G. Ellis, Corrado Tamburino

October 31, 2016

Presentation TCT 2016

Outcome Registries IV: The UK Absorb Registry

Presenter: Stephen G. Ellis, Corrado Tamburino, Andreas Baumbach

October 31, 2016

Presentation TCT 2016

Outcome Registries III: 2-Year Results From ASSURE

Presenter: Stephen G. Ellis, Corrado Tamburino, Detlef G. Mathey

October 31, 2016

Presentation TCT 2016

Outcome Registries II: Long-term Outcomes From ABSORB EXPAND and STEMI First

Presenter: Stephen G. Ellis, Corrado Tamburino, Robert-Jan van Geuns

October 31, 2016

Presentation TCT 2016

Outcome Registries I: Extended Results From ABSORB EXTEND

Presenter: Stephen G. Ellis, Corrado Tamburino, Alexandre Abizaid

October 31, 2016

Presentation TCT 2016

ABSORB China Clinical Outcomes at 2 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Runlin Gao

October 31, 2016

Presentation TCT 2016

ABSORB II Clinical Outcomes at 3 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Bernard R. Chevalier

October 31, 2016

Presentation TCT 2016

No Metallic Implants Anymore: The Case for Bioresorbable Scaffolds and ESPRIT I: Results

Presenter: Tony Das, Koen Deloose, Michael R. Jaff

October 31, 2016

Presentation TCT 2016

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Presenter: Stephen G. Ellis, Corrado Tamburino, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

Failure Modes of Bioresorbable Scaffolds: From the Obvious (Strut Thickness Considerations) to the Novel (Intraluminal Scaffold Dismantling)

Presenter: Elazer R. Edelman, Juan F. Granada

October 31, 2016

Presentation TCT 2016

Assessment and Implications of Vasomotion: Implications for BRS

Presenter: Elazer R. Edelman, Juan F. Granada, Habib Samady

October 31, 2016

Presentation TCT 2016

Benchtop Testing of BRS Mechanical Properties (General and Absorb Specific): Expansion, Recoil, Side Branches, and More

Presenter: Elazer R. Edelman, Juan F. Granada, Richard J. Rapoza

October 31, 2016

Presentation TCT 2016

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing II: Biomechanical Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing I: Pathologic Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Renu Virmani

October 31, 2016

Presentation TCT 2016

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

Presenter: Michael J. Cowley, Franz-Josef Neumann, Joel Sainsous

October 31, 2016

Presentation TCT 2016

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

Presenter: Antonio L. Bartorelli, Kenneth Chin, Jens Wiebe

October 31, 2016

Advertisement

The Great Absorb Debate: Is Absorb Ready To Be Used In Most Patients And Lesions? Yes With Proper Technique And Planning, Nearly All PCI Patients Can Benefit From BVS!

Outcome Registries VII: IT-DISAPPEARS

Outcome Registries VI: France ABSORB

Outcome Registries V: New Insights From GHOST

Outcome Registries IV: The UK Absorb Registry

Outcome Registries III: 2-Year Results From ASSURE

Outcome Registries II: Long-term Outcomes From ABSORB EXPAND and STEMI First

Outcome Registries I: Extended Results From ABSORB EXTEND

ABSORB China Clinical Outcomes at 2 Years

ABSORB II Clinical Outcomes at 3 Years

No Metallic Implants Anymore: The Case for Bioresorbable Scaffolds and ESPRIT I: Results

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Failure Modes of Bioresorbable Scaffolds: From the Obvious (Strut Thickness Considerations) to the Novel (Intraluminal Scaffold Dismantling)

Assessment and Implications of Vasomotion: Implications for BRS

Benchtop Testing of BRS Mechanical Properties (General and Absorb Specific): Expansion, Recoil, Side Branches, and More

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing II: Biomechanical Perspectives

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing I: Pathologic Perspectives

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content